Search the Newsreel

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

MRNA Stock Closes Down On Profit-Taking Following 20% Weekly Rally And Hantavirus Buzz

Capital World Investors reports 5.6% Moderna (MRNA) stake in Schedule 13G filing

Capital World Investors, an investment management entity, has reported a 5.6% beneficial ownership stake in Moderna, Inc. (MRNA) through a Schedule 13G filing. This represents 22,276,996 shares out of 396,786,259 outstanding shares, with the firm holding sole voting power over 22,264,639 shares and sole …

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

Moderna: I'm Still On The Sidelines, But Here's What Would Change My Mind (NASDAQ:MRNA)

Moderna faces significant valuation challenges, requiring flawless execution and rapid margin expansion from its late-stage pipeline to justify its $20B+ market capitalization. While the FDA approval of mFLUSIVA is a milestone, its projected $1 billion peak sales are a best-case scenario given market competition …

Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. significantly increased its stake in Moderna (NASDAQ: MRNA) by 1,387.6% in Q2, acquiring an additional 22,590 shares, bringing its total to 24,218 shares valued at $1.696 million. This comes as institutional investors now own 75.33% of Moderna's stock. The company …

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales

Moderna CEO Stéphane Bancel exercised stock options for 751,715 shares and subsequently sold 499,246 shares under a pre-arranged Rule 10b5-1 trading plan. The sales, totaling approximately $28.72 million, were conducted between $55.58 and $59.34 per share to cover exercise costs, withholding taxes, and transaction …

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Moderna's Q2 2026 earnings call focused on two main priorities: maintaining revenue growth while cutting costs and advancing late-stage pipeline programs. The company reported revenues of $145 million, exceeding estimates, and a GAAP loss of $1.97 per share, matching expectations. Moderna reiterated its target …

The flu shot finally gets an upgrade

Moderna's new mRNA flu vaccine has been approved by the FDA, representing a significant public health advancement. This mRNA vaccine is expected to offer better protection against the flu compared to traditional vaccines because it can be produced faster, better addressing the rapid mutation …

The mRNA technology behind Moderna’s Covid vaccine reaches the flu

The FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine for adults 50 and older, similar to their Covid-19 vaccine. This new vaccine offers a faster manufacturing process for annual flu shot updates and aims to enhance protection for vulnerable populations, despite causing …

What Moderna is and how it built its mRNA vaccine platform

Moderna, founded in 2010, is a Cambridge-based biotechnology company that pioneered mRNA medicine, becoming a global pharmaceutical player through its widely distributed Covid-19 vaccine. Its core thesis is that mRNA technology can be quickly adapted to target a wide range of diseases, leading to …

Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock

Moderna's mRNA-based flu vaccine, mFLUVISA, has received FDA approval for seasonal influenza prevention in adults 50-64 (traditional approval) and 65+ (accelerated approval). This approval follows an initial refusal-to-file letter from the FDA in February, which was later rescinded after industry criticism. The vaccine is …

Moderna, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MRNA) 2026-08-06

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna has received U.S. FDA approval for its influenza vaccine, mFLUSIVA (mRNA-1010), for use in adults 50 years and older. This marks Moderna's fifth approved product globally and fourth FDA-approved product, making it the first mRNA-based flu vaccine. The company anticipates mFLUSIVA will be …

Moderna secures FDA approval for its first mRNA influenza vaccine

Moderna has received FDA approval for mFLUSIVA, its first mRNA-based influenza vaccine, for adults aged 50 and over. This marks Moderna's fourth FDA-approved product and its fifth authorized product worldwide, with distribution expected to begin soon for the 2026-2027 respiratory virus season. The approval …

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Process

The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first mRNA flu shot to receive approval, following a challenging review process. The vaccine, which uses the same technology as Moderna's COVID-19 shots, is expected to …

Moderna’s mRNA Flu Shot Wins US Approval in FDA Turnaround

Moderna Inc. has received US regulatory approval for its mRNA-based flu vaccine. The vaccine is approved for adults aged 50 and over, with traditional approval for ages 50-64 and accelerated approval for those 65 and older. This marks a significant victory for Moderna, especially …

US FDA approves first mRNA flu shot from Moderna

The U.S. Food and Drug Administration has approved Moderna's mFlusiva, making it the first mRNA-based vaccine for seasonal flu. The shot is approved for individuals aged 50 and older, with a traditional approval for ages 50-64 and an accelerated approval for those 65 and …

Moderna Appeals District Court Infringement Judgment over COVID Vaccines

Moderna has appealed a District Court judgment concerning patent infringement related to its COVID-19 vaccines, arguing that the U.S. government, not Moderna, should bear the liability under 28 U.S.C. § 1498(a). The company claims that its Spikemax® vaccine was developed and distributed "for the …

Moderna, Inc. SEC Filing (Aug 5, 2026)

This article reports on a Form 144 SEC filing by Moderna, Inc. (MRNA) on August 5, 2026. The filing indicates a proposed sale of 499,246 shares of common stock with an aggregate market value of $28,956,268.00, resulting from a stock option exercise by an …

Moderna Advances Ebola Vaccine Into Human Testing

Moderna has initiated a Phase 1 clinical trial for its investigational Ebola vaccine, mRNA-1469, which targets the Bundibugyo ebolavirus and has no currently licensed vaccines. This advancement follows a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to $50 million. …

Moderna, Inc. $MRNA Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP increased its stake in Moderna (MRNA) by 74.7% during the first quarter, now owning 168,077 shares worth approximately $8.5 million. Despite beating quarterly revenue and EPS expectations, Moderna remains unprofitable, and analysts maintain a "Reduce" rating with an average price …

Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak

Moderna has initiated a Phase 1 clinical trial for an Ebola vaccine, mRNA-1469, targeting the Bundibugyo strain prevalent in the Democratic Republic of the Congo. The trial, conducted in Canada with approximately 80 participants, will assess the vaccine's safety and tolerability using the same …

Moderna starts Phase 1 trial of mRNA Bundibugyo Ebola vaccine

Moderna has initiated a Phase 1 clinical trial for its mRNA-1469 vaccine, targeting the Bundibugyo ebolavirus strain for which no approved vaccine currently exists. The trial, backed by up to $50 million from CEPI, will enroll approximately 80 healthy adults in Canada to assess …

Health Canada approves clinical trial for Moderna’s mRNA Ebola vaccine

Health Canada has approved Moderna to begin a Phase I clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus, which is causing an outbreak in the Democratic Republic of the Congo. Canada is the second country, after the U.K., …

Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna has initiated its first human trial for an experimental vaccine targeting the Bundibugyo ebolavirus, a strain responsible for over 1,650 deaths and currently lacking an approved vaccine. The mRNA-based vaccine, mRNA-1469, is being tested in Canada on approximately 80 healthy adults to assess …

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Moderna has initiated a Phase 1 clinical trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus (BDBV), a strain of Ebola with no currently licensed vaccines. The trial, conducted in Canada, is part of an expanded collaboration with CEPI, which has committed up to …

Moderna vaccinates first participants in trial for Ebola strain with no vaccine

Moderna has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine, mRNA-1469, designed to prevent Bundibugyo ebolavirus (BDBV) disease, a strain of Ebola for which no licensed vaccines currently exist. The study will assess the safety, tolerability, and immunogenicity of …

Moderna Begins Human Trial of Experimental Ebola Vaccine in Canada

Moderna has initiated human trials in Canada for an experimental Ebola vaccine, which is the second candidate to enter clinical trials for the strain causing the current outbreak in the Democratic Republic of Congo. The vaccine utilizes Moderna's mRNA platform and is being tested …

Sei Investments Co. Acquires 55,939 Shares of Moderna, Inc. $MRNA

Sei Investments Co. increased its stake in Moderna, Inc. by 76.2% in the first quarter, acquiring 55,939 additional shares to bring its total holdings to 129,395 shares valued at approximately $6.6 million. Despite this institutional buying, company insiders have sold a significant number of …

Moderna, Inc. (MRNA) Stock Analysis: Exploring a 9.75% Potential Downside in the Biotech Leader

Moderna, Inc. (MRNA) is a biotech leader facing a potential 9.75% downside from its current trading price of $54.82, according to analyst targets. Despite its innovative mRNA technology and strategic partnerships, the company has a negative forward P/E ratio and concerning return on equity, …

Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says

RBC analysts indicate that Moderna (MRNA) is expected to encounter multiple challenges in its vaccine sector in the near to medium term. The article, reserved for members, suggests these headwinds could impact the company's performance, despite recent news about narrowed Q2 losses and increased …